In an A20 tumor mouse model, the systemically administrated engineered bacteria were able to home to, and engraft in, tumors and be reliably and chronically activated by a brief non-invasive FUS treatment to release anti-CTLA-4 and anti-PD-L1 and significantly suppress tumor growth. The gene discussed is CTLA4; the disease is neoplasm.